Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Fleseriu

Showing results (231-240 of 268) with videos related to

Pageof 27
Sort By:
Pituitary|November 7, 2015
Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's diseaseMaria Fleseriu, Rosario Pivonello, Jacques Young, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 13, 2020
OFF-LABEL USE AND MISUSE OF TESTOSTERONE, GROWTH HORMONE, THYROID HORMONE, AND ADRENAL SUPPLEMENTS: RISKS AND COSTS OF A GROWING PROBLEMMichael S Irwig, Maria Fleseriu, Jacqueline Jonklaas, et al.
The Lancet. Diabetes & Endocrinology|September 28, 2014
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trialMônica R Gadelha, Marcello D Bronstein, Thierry Brue, et al.
Frontiers in Endocrinology|October 25, 2023
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's diseaseRichard A Feelders, Maria Fleseriu, Pinar Kadioglu, et al.
Pituitary|January 25, 2025
Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studiesMaria Fleseriu, Rosario Pivonello, John Newell-Price, et al.
Pituitary|July 20, 2021
Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomasNicholas A Tritos, Pouneh K Fazeli, Ann McCormack, et al.
Pituitary|May 21, 2025
Correction to: Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studiesMaria Fleseriu, Rosario Pivonello, John Newell-Price, et al.
Endocrine Reviews|April 8, 2022
Clinical Biology of the Pituitary AdenomaShlomo Melmed, Ursula B Kaiser, M Beatriz Lopes, et al.
Journal of the Endocrine Society|April 14, 2025
Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE studyMaria Fleseriu, Richard J Auchus, Wenyu Huang, et al.
European Journal of Endocrinology|November 2, 2020
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of responseSabrina Chiloiro, Antonella Giampietro, Federica Mirra, et al.
Pageof 27

Showing results (231-240 of 268) with videos related to

Sort By:
Pageof 27
Pituitary|November 7, 2015
Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's diseaseMaria Fleseriu, Rosario Pivonello, Jacques Young, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 13, 2020
OFF-LABEL USE AND MISUSE OF TESTOSTERONE, GROWTH HORMONE, THYROID HORMONE, AND ADRENAL SUPPLEMENTS: RISKS AND COSTS OF A GROWING PROBLEMMichael S Irwig, Maria Fleseriu, Jacqueline Jonklaas, et al.
The Lancet. Diabetes & Endocrinology|September 28, 2014
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trialMônica R Gadelha, Marcello D Bronstein, Thierry Brue, et al.
Frontiers in Endocrinology|October 25, 2023
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's diseaseRichard A Feelders, Maria Fleseriu, Pinar Kadioglu, et al.
Pituitary|January 25, 2025
Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studiesMaria Fleseriu, Rosario Pivonello, John Newell-Price, et al.
Pituitary|July 20, 2021
Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomasNicholas A Tritos, Pouneh K Fazeli, Ann McCormack, et al.
Pituitary|May 21, 2025
Correction to: Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studiesMaria Fleseriu, Rosario Pivonello, John Newell-Price, et al.
Endocrine Reviews|April 8, 2022
Clinical Biology of the Pituitary AdenomaShlomo Melmed, Ursula B Kaiser, M Beatriz Lopes, et al.
Journal of the Endocrine Society|April 14, 2025
Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE studyMaria Fleseriu, Richard J Auchus, Wenyu Huang, et al.
European Journal of Endocrinology|November 2, 2020
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of responseSabrina Chiloiro, Antonella Giampietro, Federica Mirra, et al.
Pageof 27